文献速递肿瘤 PET/CT

颗粒酶B PET/CT显像评估胃癌免疫治疗早期反应

Granzyme B PET/CT Imaging Evaluates Early Response to Immunotherapy in Gastric Cancer.
PubMed 文献 · J Nucl Med · 2024-11-01

研究开发靶向颗粒酶B的PET/CT探针[68Ga]Ga-NOTA-GSI,对40例III-IV期胃癌患者在免疫治疗2或3周期后行PET/CT,按RECIST 1.1评估疗效,发现应答者原发灶和转移淋巴结的SUVmax及靶本比高于非应答者,TBRtumor为独立预测因素。

要点

  • 应答者原发灶SUVmax-t为2.49±0.58,高于非应答者的1.55±0.48(P=0.000)。
  • SUVmax-t的AUC为0.886,阈值2.05时灵敏度81.0%、特异度84.2%。
  • TBRtumor是多变量logistic回归中治疗反应的独立预测因素(P=0.03)。

核心结论

  • [68Ga]Ga-NOTA-GSI PET/CT是预测胃癌患者联合免疫治疗早期反应的有前景工具。

研究设计与样本

  • 研究纳入72例III-IV期胃癌患者,在免疫治疗2或3周期后行[68Ga]Ga-NOTA-GSI PET/CT,最终40例纳入分析。
  • 测量原发肿瘤SUVmax-t、转移淋巴结SUVmax-LN及正常组织(肝和血池)SUVmax,计算原发肿瘤的TLRtumor和TBRtumor及转移淋巴结的TLRLN和TBRLN。
  • 全疗程治疗结束后1周内按RECIST 1.1评估治疗反应,采用Wilcoxon秩和检验比较应答者与非应答者的PET/CT参数,用ROC曲线分析诊断效能,双侧P<0.05为有统计学意义。

主要发现

  • 应答者原发灶SUVmax-t为2.49±0.58,非应答者为1.55±0.48(P=0.000)。
  • 应答者TLRtumor为2.24±0.48,非应答者为1.74±0.67(P=0.007)。
  • 应答者TBRtumor为1.38±0.43,非应答者为0.90±0.23(P=0.000)。
  • 应答者转移淋巴结SUVmax-LN为2.24±0.99,非应答者为1.42±0.55(P=0.003);应答者TBRLN为1.28±0.68,非应答者为0.83±0.32(P=0.012)。
  • ROC分析显示SUVmax-t、TBRtumor、TLRtumor、SUVmax-LN、TLRLN、TBRLN的AUC分别为0.886、0.866、0.746、0.772、0.648、0.731;SUVmax-t阈值2.05时灵敏度81.0%、特异度84.2%;多变量logistic回归显示TBRtumor为治疗反应的独立预测因素(P=0.03)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In several malignancies, only a limited number of patients respond to immune checkpoint inhibitors. Predicting and monitoring responses to these inhibitors represent an unmet clinical need. Here, we developed a PET/CT probe targeting granzyme B, [68Ga]Ga-NOTA-Gly-Gly-Gly-Ile-Glu-Pro-Asp-CHO (GSI), and aimed to investigate whether it can be used to monitor the effects of immune checkpoint inhibitors early in the course of therapy. Methods: Seventy-two patients with gastric cancer (stages III-IV) were recruited for [68Ga]Ga-NOTA-GSI PET/CT imaging after 2 or 3 cycles of the immunotherapy, and 40 patients were included in the final analysis. The SUVmax of primary tumors (SUVmax-t), SUVmax of metastatic lymph nodes (SUVmax-LN), and SUVmax of normal tissues (liver and blood pool) were measured, and their target-to-liver background ratio (TLR) and target-to-blood background ratio (TBR) were denoted for primary tumors as TLRtumor and TBRtumor and for metastatic lymph nodes as TLRLN and TBRLN, respectively. The treatment responses were assessed within 1 wk after full-course treatment according to RECIST version 1.1. Wilcoxon rank-sum tests were used to compare the PET/CT parameters between responders and nonresponders. Receiver operating characteristic curve analysis was used to assess the diagnostic efficacy of [68Ga]Ga-NOTA-GSI PET/CT parameters in identifying responders. Two-tailed P value of less than 0.05 was considered statistically significant. Results: We found that SUVmax-t, TLRtumor, TBRtumor, SUVmax-LN, and TBRLN were higher in responders than in nonresponders (2.49 ± 0.58 vs. 1.55 ± 0.48, P = 0.000; 2.24 ± 0.48 vs. 1.74 ± 0.67, P = 0.007; 1.38 ± 0.43 vs. 0.90 ± 0.23, P = 0.000; 2.24 ± 0.99 vs. 1.42 ± 0.55, P = 0.003; and 1.28 ± 0.68 vs. 0.83 ± 0.32, P = 0.012, respectively). According to receiver operating characteristic curve analysis, the area under the curve for SUVmax-t, TBRtumor, TLRtumor, SUVmax-LN, TLRLN, and TBRLN was 0.886, 0.866, 0.746, 0.772, 0.648, and 0.731, respectively. The threshold of SUVmax-t was 2.05, and its sensitivity and specificity were 81.0% and 84.2%, respectively. In addition, multivariate logistic regression indicated that TBRtumor was an independent predictor of treatment response (P = 0.03). Conclusion: Our results indicated that [68Ga]Ga-NOTA-GSI PET/CT is a promising tool for predicting early response to combined immunotherapy in gastric cancer patients.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Liu Q, Xu X, Yang Z, et al. Granzyme B PET/CT Imaging Evaluates Early Response to Immunotherapy in Gastric Cancer. J Nucl Med. 2024. PMID: 39389628. doi:10.2967/jnumed.124.267529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。